San Anselmo

Researchers are studying the use of ketamine to treat phantom limb pain, a severe and often persistent pain experienced by over half of amputees. This research follows anecdotal evidence suggesting ketamine might provide long-lasting relief from symptoms. The study aims to better understand ketamine's role as a treatment for this challenging condition, which currently relies heavily on opioids and other pain medications with limited success. The trial is conducted as a Phase 2 and Phase 3 clinical study involving 25-30 participants living near study sites in the Bay Area, Los Angeles, Albuquerque, and Sacramento. Participants will receive up to 16 intramuscular ketamine sessions over six months, with dosages carefully determined and adjusted in the initial session but not exceeding 120 mg. The timing between ketamine sessions depends on individual response, requiring at least seven days of remission before the next treatment. Support and integration sessions accompany the medication administration, similar to ketamine-assisted psychotherapy methods practiced by the clinicians conducting the study. Throughout the study, participants' phantom limb pain and emotional impacts will be closely monitored using various assessment tools, including the McGill Pain Questionnaire over six months with an additional 12-month follow-up. Researchers will track symptom changes, medication adherence, and safety through laboratory tests and daily diaries. The study includes thorough monitoring of liver and kidney function, cardiovascular status, and medication interactions to ensure participant safety during the trial.